What it's for (Indications)
- Chlordiazepoxide and clidinium is a fixed-dose combination medication primarily indicated as adjunctive therapy for the management of gastrointestinal disorders in which emotional factors are believed to play a significant role.
- This includes, but is not limited to, the treatment of peptic ulcer, irritable bowel syndrome (IBS), and acute enterocolitis.
- The chlordiazepoxide component, a benzodiazepine, targets the anxiety and tension that can exacerbate these conditions, providing an anxiolytic and sedative effect.
- Concurrently, the clidinium component, an anticholinergic agent, acts to reduce gastrointestinal spasms, hypermotility, and acid secretion, thereby alleviating associated physical symptoms such as abdominal pain, cramping, and diarrhea.
- While its role in peptic ulcer disease has diminished with the advent of H.
- pylori eradication and proton pump inhibitors, its utility in IBS, particularly for symptom relief of abdominal pain and cramping, remains a consideration in some treatment paradigms when emotional overlay is present.
- This combination aims to address both the psychogenic and somatic aspects of these complex GI conditions, offering a dual-action approach to symptom management.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage should be individualized based on diagnosis and patient response to achieve maximum beneficial effects. The usual maintenance dose is 1 or 2 capsules, 3 or 4 times a day, administered before meals and at bedtime. For geriatric patients, dosage should be limited to the smallest effective amount to prevent ataxia, oversedation, or confusion. The initial dose for elderly patients should not exceed 2 capsules per day, to be increased gradually as needed and tolerated. Discontinuation or dosage reduction should be done gradually. |
Safety & Warnings
Common Side Effects
- Common side effects include drowsiness, unsteadiness (ataxia), loss of balance, and confusion, particularly in the elderly and debilitated.
- Other reported adverse reactions include vertigo, gastrointestinal upset, visual disturbances, headache, rash, sexual disturbances, and syncope (fainting).
- Rare side effects reported are blood disorders and jaundice.
Serious Warnings
- Black Box Warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
- Concomitant Use with Opioids: Co-administration with opioids can lead to profound sedation, respiratory depression, coma, and death.
- Such use should be reserved for cases where alternative treatment options are inadequate, with strict limitations on dosage and duration, and close monitoring for signs of respiratory depression and sedation.
- Pregnancy: Should be avoided during pregnancy unless no safer alternative is available and the potential benefit justifies the risk.
- Driving & Operating Machinery: Patients should avoid driving or operating heavy machinery due to potential impairment of ability.
- Alcohol Consumption: Concurrent use of alcohol should be avoided.
- Specific Patient Populations: Caution is advised in patients with respiratory insufficiency, renal impairment, or hepatic impairment.
- Elderly and debilitated patients are at an increased risk of dose-related adverse reactions, including ataxia, oversedation, and confusion, and require careful dosage adjustment.
- Long-Term Use: Avoid long-term use.
How it Works (Mechanism of Action)
The therapeutic action of chlordiazepoxide and clidinium results from the synergistic effects of its two active components, each acting via distinct pharmacological pathways. Chlordiazepoxide, a benzodiazepine, exerts its primary effects by potentiating the activity of gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the central nervous system (CNS). It binds to specific benzodiazepine receptor sites on the GABA-A receptor complex, leading to an increased frequency of chloride channel opening. This influx of chloride ions hyperpolarizes the neuronal membrane, thereby decreasing neuronal excitability and resulting in anxiolytic, sedative, and skeletal muscle relaxant properties. This action helps to alleviate the anxiety and tension associated with functional gastrointestinal disorders. Clidinium, on the other hand, is an anticholinergic (antimuscarinic) agent that competitively antagonizes the actions of acetylcholine at postganglionic muscarinic receptors. In the gastrointestinal tract, this antagonism leads to a reduction in smooth muscle spasm and tone, decreased gastrointestinal motility, and a moderation of gastric acid and other secretory gland secretions. By targeting both the central nervous system (with chlordiazepoxide) and the peripheral gastrointestinal system (with clidinium), the combination effectively addresses both the psychogenic and somatic symptoms often observed in conditions like irritable bowel syndrome and peptic ulcer disease.
Commercial Brands (Alternatives)
No other brands found for this formula.